Your session is about to expire
← Back to Search
Observational (biospecimen collection, medical record review) for Chronic Lymphocytic Leukemia
Summary
This study evaluates the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer that begin in cells of the immune system. CLL/SLL and the medications used to treat these conditions may change the way vaccines work in a patient's body. The purpose of this study is to find out if patients with CLL/SLL make antibodies, or have an immune response, to the SARS-CoV-2 vaccines. Information gained from this study may help researchers better understand how effective the vaccines work in preventing COVID-19 (coronavirus disease 2019) in patients with CLL and SLL.
- Chronic Lymphocytic Leukemia
- Lymphoma
Timeline
Treatment Details
Trial Design
Find a Location
Who is running the clinical trial?
Share this study with friends
Copy Link
Messenger